Screener / SEC EDGAR /CIK 0001991792 /10-K filed Feb 27, 2026, compared with Mar 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CG Oncology, Inc. CGON

Compare with peers Embed
FY2025 at a glance

Sales up 254.7%, free cash flow down to -$132.5M

XBRL, from each 10-K
RevenueStatements
$4.0M from $1.1M in FY2024
FY2023FY2025
Net incomeStatements
-$161.0M from -$88.0M in FY2024
FY2023FY2025
Free cash flowStatements
-$132.5M from -$78.9M in FY2024
FY2023FY2025
EPS (diluted)Statements
$-2.08 from $-1.41 in FY2024
FY2023FY2025
Operating marginStatements
-4722.1% from -10067.3% in FY2024
FY2023FY2025
Total debtStatements
$3.0M from $0 in FY2024
FY2023FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (34)
EPS (ttm)
-2.76
Sales (ttm)
6.2M
Net income (ttm)
-237.5M
Sales growth
+255%
EPS growth
-
Sales Q/Q
-3.7%
Free cash flow
-189.2M
Gross margin
-
Oper. margin
n/m
Net margin
n/m
FCF margin
n/m
R&D / sales
2887.2%
Dividend
-
Debt/Eq
0.00
Curr. ratio
21.70
Cash
28.2M
Op. cash flow (ttm)
-187.3M
EBITDA
-189.3M
EBITDA margin
n/m
Net debt
-25.2M
Quick ratio
21.67
Interest cover
n/m
FCF after stock pay
-159.2M
Goodwill / assets
1.3%
Stock pay / sales
660.3%
Shares out.
89.3M
Shares Y/Y
+23.7%
Book / share
11.09
Cash / share
0.32
Sales / share
0.07
Asset turnover
0.01
Days sales out.
62

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2023 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 4.0M +345.0% a year Net income -161.0M
FY2023 revenue 204K · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-079498 FY2023 net income -48.6M · NetIncomeLoss, 0001193125-26-079498 204K FY2023 FY2024 revenue 1.1M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-079498 FY2024 net income -88.0M · NetIncomeLoss, 0001193125-26-079498 1.1M FY2024 FY2025 revenue 4.0M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-079498 FY2025 net income -161.0M · NetIncomeLoss, 0001193125-26-079498 4.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2023 to FY2025 (2 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $759.5M
  • − All liabilities $39.0M
  • = Net current asset value $720.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $752.6M
  • − Goodwill $10.3M
  • − Other intangible assets $575K
  • = Tangible book value $741.7M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

CGON against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+255%3rd of 155 · median +10.5%
Return on equity
-5.2%18.5%
-24.0%120th of 144 · median 9.2%
Debt / equity (less is better)
1.160.42
0.001st of 108 · median 0.69
CGON and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
OCUL Ocular Therapeutix, Inc$50.4M -18.5%87.3%-648.6%-74.1%-530.0%0.17
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
SRRK Scholar Rock Holding Corp$570K -----1.16
All 162 companies in the group

Where the $4.0M of revenue came from

by product, year to Dec 31, 2025

  • Commercial and Development Revenue $3.2M · 80%
  • License and Collaboration Revenue $806K · 20%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2024 · 10-K XBRL, year-end balances

Return on equity -21.4% FY2024: -12.0% net income ÷ equity
Net margin -3985.0% FY2024: -7729.5% profit per $ of sales: -161.0M ÷ 4.0M
Asset turnover 0.01× FY2024: 0.00× sales per $ of assets: 4.0M ÷ 791.6M
Leverage 1.05× FY2024: 1.03× assets per $ of equity: 791.6M ÷ 752.6M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -3851.1% vs 6.8%
  • Return on equity below 15%
    -24.0%
  • A profit in 0 of 3 years
Net margin, FY2023 to FY2025: -23827.0% to -3985.0%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -1852.2× interest expense
  • Debt smaller than equity
    Debt / equity 0.00 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 21.70
  • More cash than debt
    Net cash $734.9M
Debt / equity at each year end, FY2023 to FY2025: 0.00 to 0.00

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

CGON's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 3. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue4.0M
FY2023: 204KFY2024: 1.1MFY2025: 4.0M FY2023FY2024FY2025
Net income-161.0M
FY2023: -48.6MFY2024: -88.0MFY2025: -161.0M FY2023FY2024FY2025
Free cash flow-132.5M
FY2023: -FY2024: -78.9MFY2025: -132.5M FY2023FY2024FY2025
Free cash flow after stock pay-159.2M
FY2023: -FY2024: -90.3MFY2025: -159.2M FY2023FY2024FY2025
EPS (diluted)-2.08
FY2023: -15.65FY2024: -1.41FY2025: -2.08 FY2023FY2024FY2025
Diluted shares77.3M
FY2023: 4.3MFY2024: 62.5MFY2025: 77.3M FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Commercial and Development Revenue 3.2M80.0% -
License and Collaboration Revenue 806K20.0% -29.2%

10-K 0001193125-26-079498, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2023FY2024FY2025
Revenue204K1.1M4.0M
R&D45.8M82.1M116.6M
SG&A9.9M33.7M73.5M
Operating income-55.4M-114.7M-190.8M
Interest expense376K-103K
Income tax1K1K-270K
Net income-48.6M-88.0M-161.0M
EPS (diluted)-15.65-1.41-2.08
Diluted shares4.3M62.5M77.3M
Depreciation & amortization17K32K1.4M
EBITDA-55.4M-114.6M-189.3M
Operating margin-27180.9%-10067.3%-4722.1%
Net margin-23827.0%-7729.5%-3985.0%
Revenue growth-+458%+255%

Balance sheet

From EDGAR
FY2023FY2024FY2025
Cash8.3M257.1M32.5M
Short-term investments179.4M484.9M709.7M
Receivables-0688K
Inventory-01.6M
Current assets194.1M754.2M759.5M
Property & equipment69K272K15.6M
Goodwill-010.3M
Other intangible assets-0575K
Total assets199.3M754.8M791.6M
Accounts payable3.2M6.5M5.7M
Current liabilities14.3M21.4M30.8M
Total debt-03.0M
Total liabilities14.5M21.4M39.0M
Shareholders' equity-123.1M733.4M752.6M
Retained earnings-129.9M-218.0M-379.0M

Cash flow

From EDGAR
FY2023FY2024FY2025
Operating cash flow-45.7M-78.7M-132.3M
Capital spending-234K134K
Free cash flow--78.9M-132.5M
Stock-based pay (added back)1.5M11.4M26.7M
Free cash flow after stock pay--90.3M-159.2M
Acquisitions--22.0M
Investing cash flow-121.2M-300.8M-245.8M
Financing cash flow87.0M628.3M153.6M

Stock-based pay and leases

From EDGAR
FY2023FY2024FY2025
Stock-based pay (expense)1.5M11.4M26.7M
Stock-based pay / revenue749.0%1001.1%660.3%
Operating lease cost232K228K699K
Operating lease cash paid219K223K588K
Right-of-use assets422K221K4.0M
Operating lease liabilities461K238K4.0M
Finance lease liabilities00-

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.